English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

The immunopeptidomic landscape of ovarian carcinomas

MPS-Authors

Kohlbacher,  Oliver
External Organizations;
Max Planck Institute for Developmental Biology, Max Planck Society;

Locator
Fulltext (public)
There are no public fulltexts available
Supplementary Material (public)
There is no public supplementary material available
Citation

Schuster, H., Peper, J. K., Boesmueller, H.-C., Roehle, K., Backert, L., Bilich, T., et al. (2017). The immunopeptidomic landscape of ovarian carcinomas. Proceedings of the National Academy of Sciences of the United States of America, 114(46), E9942-E9951. doi:10.1073/pnas.1707658114.


Cite as: http://hdl.handle.net/21.11116/0000-0002-1A7A-9
Abstract
Immunotherapies, particularly checkpoint inhibitors, have set off a revolution in cancer therapy by releasing the power of the immune system. However, only little is known about the antigens that are essentially presented on cancer cells, capable of exposing them to immune cells. Large-scale HLA ligandome analysis has enabled us to exhaustively characterize the immunopeptidomic landscape of epithelial ovarian cancers (EOCs). Additional comparative profiling with the immunopeptidome of a variety of benign sources has unveiled a multitude of ovarian cancer antigens (MUC16, MSLN, LGALS1, IDO1, KLK10) to be presented by HLA class I and class II molecules exclusively on ovarian cancer cells. Most strikingly, ligands derived from mucin 16 and mesothelin, a molecular axis of prognostic importance in EOC, are prominent in a majority of patients. Differential gene-expression analysis has allowed us to confirm the relevance of these targets for EOC and further provided important insights into the relationship between gene transcript levels and HLA ligand presentation.